BIOFUTUR 278 • JUIN 2007 62
SI VOUS SOUHAITEZ PARTICIPER À CETTE RUBRIQUE Merci
de contacter José Fernandez au 01 48 67 20 51 ouj.fernandez@
infomediapublishing.fr
Motion Computing lance le premier assistant clinique mobile spécifiquement conçu pour les praticiens hospitaliers
Le Motion C5 a été développé sur la base de retours d’expérience de milliers de praticiens hospitaliers à tra- vers le monde, recueillis dans le cadre d’études ethno- graphiques menées par Intel et Motion. Il répond à des besoins extrêmement spécifiques :
• résistant aux chocs et aux chutes, son châssis est en alliage de magnésium ;
• entièrement hermétique et nettoyable, ses surfaces lisses, dépourvues de ports et de renfoncements pro- pices à la prolifération d’agents pathogènes sont recouvertes d’un revêtement en résine résistant aux désinfectants ;
• sécurisé et fiable pour garantir la confidentialité des données des patients, il permet un contrôle d’accès rigoureux grâce à son lecteur d’empreintes digitales ;
• suffisamment compact, léger et polyvalent pour être emmené partout, il ne pèse que 1,4 kg ;
• doté des technologies mobiles les plus avancées, il permet une gestion de l’in- formation en temps réel, notamment au pied du patient, sans repasser par l’ordina- teur du service, et ce grâce à ses fonctionnalités Bluetooth, Wi-Fi, identification par radio fréquence (RFID) et lecteur de code barre (en option) ;
• ergonomique pour permettre une prise en main facile et un réel dialogue avec le patient, il propose un appa- reil photo numérique 2 mégapixels intégré, un grand écran de 10,4 pouces pour consulter, partager les don- nées médicales et prendre des notes manuscrites grâce à son stylet numérique.
Conçu avec et pour les professionnels de santé, le Motion C5 rationalise le fonctionnement hospitalier, réduit le temps perdu en tâches administratives et la charge de travail de tout le personnel soignant tout en permettant une amélioration significative de la qualité des soins.
Pour plus d’informations : www.motioncomputing.fr
Nouveaux produits
Mass Spec Analytical advances forensic science through the development of innovative technology Combined expertise leads to fast and sensitive detec- tion methods for airport authorities, police and drug enforcement agencies.
Scientists from Mass Spec Analytical, Bristol, UK, a company specialising in trace analysis for forensic cases, have developed Scentinel®, a mobile, multi-purpose detection system that can rapidly identify compounds at sub-nanogram levels. The system will make it quic- ker and easier for forensic scientists to prove the exis- tence of specific compounds on crime scene samples, providing more reliable evidence for casework studies and helping to solve more crimes.
Scentinel is based on Applied Biosystems/MDS SCIEX’s highly sensitive tandem mass spectrometer, the API 2000™ system, and has been developed for the detec- tion of trace amounts of drugs of abuse and other sub- stances, including explosives. Simplification of the assays with the front-end ionisation sources and mass spec- trometry systems from Applied Biosystems/MDS SCIEX has drastically reduced the risk of contamination, which is always a major problem in the analysis of minute amounts of any substance, including drugs of abuse.
To date, Mass Spec Analytical has used the methodo- logy to provide evidence for more than five thousand forensic cases, detecting tiny amounts of drugs or explo- sives on bank notes, vehicles, packages, clothing and paperwork, for customs, police and other similar agen- cies and, more recently, for analysing tickets and boar- ding passes at airports. Such is the sensitivity of the technology that it can successfully detect even the tiniest residual traces transferred to a boarding pass from the fingers of somebody who has handled explosives.
The method is fast, analysing a thousand tickets an hour, and simple, providing instant yes/no results that do not require special expertise or complicated analysis.
Applied Biosystems/MDS SCIEX is the recognised lea- der worldwide in providing tandem mass spectrometry (MS/MS) technology ideally suited to trace detection.
MS/MS has become the analytical method of choice in the pharmaceutical and environmental industries and is well established in the field of forensic analysis. Its greatest assets are excellent sensitivity and selectivity and real time analysis without sample preparation.
For further information, please contact:
abdirect@eur.appliedbiosystems.com http://europe.appliedbiosystems.com
© DR
© DR© DR
pDG helper & packaging vectors for AAV production Vectors such as pDG, pDM, pDP1rs to pDP6rs and pDG without a heparin binding motive are immediately avai- lable from PlasmidFactory.
The vectors are produced in reproducible quality by Plas- midFactory´s standardized manufacturing technology, which includes LPS-endotoxin removal and cultivation without any animal derived component. Homogeneous products of precisely defined quality are assured by the proprietary CGE analysis technology. The service includes the complete characterization of the products by LAL test (LPS-endotoxin), BCA test (total protein), UV spectro- scopy, restriction analysis, detection of RNA and bacterial chromosomal DNA using AGE, and sequencing (partial).
Co-transfection of cells with pDG and AAV vector plas- mids (two plasmid system) is sufficient for the reprodu- cible production of infectious recombinant AAV, since the pDG vectors contain all AAV and adenovirus functions required for amplification and packaging of AAV vector plasmids. Triple-transfection is no longer necessary. Fur- thermore, super-infection with a helper virus – in contrast to traditional systems – is also dispensable. For optimal co-transfection results homogenous, intact supercoiled plas- mid DNA is a prerequisite, which is manufactured up to GMP Grade Quality by PlasmidFactory.
The pDG vectors are manufactured under license from the German Cancer Research Centre (DKFZ), Heidelberg.
For further information: www.plasmidfactory.com 14-nouvprod278 23/05/07 8:59 Page 62
Cet article des Editions Lavoisier est disponible en acces libre et gratuit sur biofutur.revuesonline.com
